W. Walker and S. Faust, Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine, Expert Review of Vaccines, vol.9, issue.12, pp.1385-13981471, 2010.
DOI : 10.1586/erv.10.141

C. Waddington, W. Walker, C. Oeser, A. Reiner, T. John et al., Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study, BMJ, vol.340, issue.may27 1, p.2649, 2010.
DOI : 10.1136/bmj.c2649

F. Roman, T. Vaman, B. Gerlach, A. Markendorf, P. Gillard et al., Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial, Vaccine, vol.28, issue.7, pp.1740-1745, 2010.
DOI : 10.1016/j.vaccine.2009.12.014

J. Garcia-sicilia, P. Gillard, A. Carmona, J. Tejedor, J. Aristegui et al., Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents, Vaccine, vol.29, issue.26, pp.4353-4361, 2011.
DOI : 10.1016/j.vaccine.2011.04.011

A. Madhun, P. Akselsen, H. Sjursen, G. Pedersen, S. Svindland et al., An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers, Vaccine, vol.29, issue.2, pp.266-273, 2010.
DOI : 10.1016/j.vaccine.2010.10.038

A. Saitoh, S. Tamura, N. Nagai, N. Tsuchida, M. Sako et al., Clinical evaluation of an AS03-adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report), J Jap Pediatr Soc, vol.115, pp.578-584, 2011.

A. Saitoh, A. Nagai, K. Tenjinbaru, P. Li, D. Vaughan et al., Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 infl uenza vaccine, Human Vaccines & Immunotherapeutics, vol.8, pp.1-11, 2012.

J. Langley, L. Frenette, L. Ferguson, D. Riff, E. Sheldon et al., Safety and Cross???Reactive Immunogenicity of Candidate AS03???Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults, The Journal of Infectious Diseases, vol.201, issue.11, pp.1644-1653, 2010.
DOI : 10.1086/652701

S. Morel, A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras et al., Adjuvant System AS03 containing ??-tocopherol modulates innate immune response and leads to improved adaptive immunity, Vaccine, vol.29, issue.13, pp.2461-2473, 2011.
DOI : 10.1016/j.vaccine.2011.01.011

C. Hannoun, F. Megas, and J. Piercy, Immunogenicity and protective efficacy of influenza vaccination, Virus Research, vol.103, issue.1-2, pp.133-138, 2004.
DOI : 10.1016/j.virusres.2004.02.025

W. Beyer, A. Palache, M. Baljet, and N. Masurel, Antibody induction by influenza vaccines in the elderly: a review of the literature, Vaccine, vol.7, issue.5, pp.385-394, 1989.
DOI : 10.1016/0264-410X(89)90150-3

L. Jackson, W. Chen, J. Stapleton, C. Dekker, W. A. Brady et al., Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons, Journal of Infectious Diseases, vol.206, issue.6, pp.811-820, 2012.
DOI : 10.1093/infdis/jis427

J. Langley, D. Reich, N. Aggarwal, D. Connor, M. Lebel et al., Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to <9 Years of Age, The Pediatric Infectious Disease Journal, vol.31, issue.8, pp.848-858, 2012.
DOI : 10.1097/INF.0b013e31825e6cd6

E. Miller, N. Andrews, L. Stellitano, J. Stowe, A. Winstone et al., Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis, BMJ, vol.346, issue.feb26 2, p.794, 2013.
DOI : 10.1136/bmj.f794

H. Nohynek, J. Jokinen, M. Partinen, O. Vaarala, T. Kirjavainen et al., AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland, PLoS ONE, vol.21, issue.3, p.33536, 2012.
DOI : 10.1371/journal.pone.0033536.t004

A. Shaikh, P. Termsarasab, C. Nwankwo, A. Rao-frisch, and B. Katirji, Atypical forms of Guillain-Barr?? syndrome and H1N1-influenza vaccination, Vaccine, vol.30, issue.22, pp.3251-3254, 2012.
DOI : 10.1016/j.vaccine.2012.03.013

K. Nicholson, K. Abrams, S. Batham, T. Clark, K. Hoschler et al., Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial, The Lancet Infectious Diseases, vol.11, issue.2, pp.91-101, 2011.
DOI : 10.1016/S1473-3099(10)70296-6

M. Ferguson, G. Risi, M. Davis, E. Sheldon, M. Baron et al., Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant, Journal of Infectious Diseases, vol.205, issue.5, pp.733-744, 2012.
DOI : 10.1093/infdis/jir641

H. Ikematsu, K. Tenjinbaru, P. Li, A. Madan, and D. Vaughn, -adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older, Human Vaccines & Immunotherapeutics, vol.27, issue.8, pp.1119-1125, 2012.
DOI : 10.1016/j.vaccine.2010.12.125
URL : https://hal.archives-ouvertes.fr/in2p3-00186195

F. Roman, T. Vaman, F. Kafeja, E. Hanon, and . Van-damme, ???Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age, Clinical Infectious Diseases, vol.51, issue.6, pp.3668-677, 2010.
DOI : 10.1086/655830